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RestagingAbstract Background: Early diagnosis and accurate staging of loco-regional and distant recur-
rence after treatment of breast cancer is decisive for further therapeutic planning. Our aim was
to evaluate the role of FDG-PET/CT in the follow up and restaging of breast cancer patients.
Methods: We retrospectively evaluated 34 female patients with a history of breast cancer. Patients
were referred for a PET/CT scan because of suspected recurrence (n= 15), whole body staging in
already conﬁrmed cases of recurrence (n= 5), follow up and reassurance in asymptomatic patients
(n= 7), follow up after local ablative therapy of liver metastases (n= 5), follow up after treatment
of bone metastases (n= 2). PET-CT ﬁndings were compared with the ﬁndings obtained by other
imaging modalities, histopathology, together with clinical and imaging follow up for at least
6 months.
Results: The PET/CT was considered pathological in 21/34 patients. Incorrect interpretations of
PET/CT images occurred in 3 patients (8.8%). PET/CT showed an overall diagnostic accuracy
of 91.2% with a sensitivity of 90.5% and a speciﬁcity of 92.3%. The PPV and NPV were 95%
and 85.7%, respectively.
Conclusion: FDG-PET/CT may play a substantial role in the restaging and follow up of patients
with breast cancer showing high sensitivity and speciﬁcity.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Breast cancer is the most prevalent cancer in female patients. It
is responsible for 15% of cancer deaths in women in western
countries, affecting not only elderly but also many younger pa-
tients, with the highest incidence among the (60–69) age group
(1).
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recurrence at some time within the course of their disease (2).
The presence of recurrent local and/or metastatic disease is
associated with a rather poor prognosis (3). Therefore the
accurate staging of local, regional and distant recurrence after
initial diagnosis and treatment is of utmost importance for fur-
ther therapeutic planning (4). Conventional imaging modality
as; mammography, chest radiography, abdominal ultrasound
(US), CT and MRI are usually the primary tools of investiga-
tion in recurrence and/or metastatic disease. Despite the accu-
racy of these imaging modalities, they are not always able to
localize the disease. Mammography, chest radiography and
US are not whole-body imaging, while CT and MRI are usu-
ally performed in a segmental fashion, making them incapable
of assessing the full extent of the disease (5). In addition, ana-
tomical imaging modalities, especially CT follow size-based
criteria to decide the malignant nature of lesions, which is lim-
ited by follow up evidence of tumour size changes (6).
[18F] Fluorodeoxyglucose Positron-emission tomography
(FDG-PET) was found to be a sensitive modality in the assess-
ment of breast cancer recurrence with a sensitivity ranging
from 89% to 100% (7). Unfortunately the lack of anatomical
localization and morphology of FDG-PET may affect its spec-
iﬁcity (8).
Combined FDG-PET/CT can provide both morphological
and metabolic information by combining anatomical imaging
from CT with functional imaging from PET (9). It has been re-
cently introduced as whole body imaging modality for examin-
ing the patients with a suspicion of recurrent breast cancer,
indicating an improved restaging accuracy and a possible im-
pact on therapy (10,11).
The objective of the current study was to evaluate retro-
spectively the clinical implementation of FDG-PET/CT in fol-
lowing up and restaging of recurrent breast cancer patients.
2. Materials and methods
2.1. Patients
The institutional review board allowed a retrospective review
of patient data sets. We retrospectively evaluated 129 female
patients of known breast cancer who underwent FDG-PET/
CT examination at PET/CT unit, Goethe University Hospital
between April 2008 and June 2010. Thirty-four of these pa-
tients were included in the study because of sufﬁcient clinical
information, and follow up were available to verify these pa-
tients. The histological subtype was invasive duct carcinoma
in all cases. The time interval between the initial diagnosis of
breast cancer and FDG-PET/CT study was 3 m-22yrs (mean
60 m). All had been previously treated by surgery, hormone
therapy, chemotherapy and/or radiotherapy. PET/CT exami-
nation was done 30 days after the last cycle of chemotherapy
to avoid false negative results due to metabolic stunning of
the tumour tissue.
The indications of FDG-PET/CT were: suspected recur-
rence of breast cancer (n= 15), whole body staging in already
diagnosed cases of recurrence (n= 5), follow up and reassur-
ance in asymptomatic patients (n= 7), follow up after local
ablative therapy of hepatic metastases (n= 5) (Radio-fre-
quency ablation (RFA) in 2 patients, Laser-induced thermal
therapy (LITT) in 3 patients), follow up after treatment ofbone metastases (n= 2). Recurrence was suspected because
of elevated tumour marker levels and/or patients’ symptoms,
and/or equivocal or suspicious ﬁndings on other imaging
studies.
2.1.1. Whole-body 18F-FDG-PET/CT technique
All patients were scanned on integrated PET/CT scanner
(Biograph 6, Siemens Medical Solutions, Erlangen, Ger-
many). Patients fasted for at least 6 h before receiving an in-
tra-venous injection of 3 MBq/kg [18F] FDG (maximum of
370 Mbq). Blood glucose level was measured before injection
of the tracer, to ensure a level below 130 mg/dl. After injec-
tion, the patients were kept lying comfortably in a quiet place
for 60 min.
A diagnostic contrast-enhanced CT scan was initially ob-
tained using the following parameters (120 mAs, 130 kV,
5 mm slice collimation), with an application of 120 mL non-
ionic contrast agent (Optiray 350 [Ioversol 74%], Covidien,
Germany) in venous phase (70 s delay). Seven studies were
performed without IV contrast due to allergy to contrast
material in 2 patients, and impaired kidney function in the
other 5 patients. This was followed by PET scan in 3-D mode
with an acquisition time of 3 min per bed position (axial
FOV16.2 cm). The imaging ﬁeld encompassed 6 to 8 bed
positions depending on patient height. Images were acquired
from the base of the skull to the mid-thigh level in the ‘‘arms-
up’’ position.
The CT acquisition was used for attenuation correction, fu-
sion and for diagnosis. The reconstructed attenuation-cor-
rected PET, CT and fused PET/CT images were viewed
using the manufacturer’s work station (Syngo (TM) software,
Siemens Medical solutions).
2.2. Image analysis
Two observers, an experienced senior radiologist and a nuclear
medicine specialist consensually reanalyzed ﬁndings on FDG-
PET/CT images. They were aware of the patient’s primary
diagnosis and study indication, but had no information
regarding the results of previous imaging modalities or pa-
tient’s disease status.
The PET/CT imaging was assessed quantitatively and qual-
itatively for areas of increased FDG uptake. The presence and
localization of any area of increased FDG uptake was re-
corded on PET/CT and each lesion was characterized as be-
nign, malignant or equivocal. A focus of increased FDG was
considered benign when related to the physiologic uptake of
FDG or to a known non-malignant process. A focus of abnor-
mal FDG activity greater than that of surrounding tissues,
which could not be related to benign or physiologic FDG up-
take or was localized in a suspicious mass on CT, was consid-
ered malignant. Any focus of FDG uptake that could not be
clearly characterized; was diagnosed as equivocal (probably
malignant or probably benign).
For visual analysis abnormal FDG uptake was deﬁned as a
substantially greater activity in the tissue than in the aortic
blood on attenuation–correction images. Maximum standard-
ized uptake value (SUV) was measured at every site of FDG
uptake. The diagnosis of malignancy was also supported by
a maximum SUV >2.5 and >3.5 for malignant extrahepatic
and intrahepatic lesions respectively (12).
Fig. 1 Eighty-six year old patient with history of breast
carcinoma 13y ago. The patient was referred for the evaluation
of new onset solitary pulmonary nodule. (a and b) PET/CT scan
showed the left upper lobe small pulmonary nodule 2.0 · 2.4 cm in
diameter, with increased glucose metabolism (SUVmax 4.2), it was
highly suspicious of malignancy. (c) Follow up CT done 1 m later
due to deterioration of the patient’s symptoms; the nodule
disappeared with newly developed bilateral pleural effusion.
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This study included patients evaluated for suspected recur-
rence, whole body staging in already diagnosed cases of recur-
rence or follow up. The disease status in these patients was
classiﬁed into three categories: no recurrence, loco-regional
recurrence and distant recurrence. Loco-regional recurrence
was deﬁned as recurrence in the ipsilateral breast, chest wall
or draining lymph nodes (axillary and supraclavicular nodes).
Distant recurrence included recurrence in the contralateral ax-
illary and supraclavicular nodes, internal mammary and medi-
astinal lymph nodes, lung, liver, bone, brain, suprarenal glands
or other organs (13).
2.2.2. Reference standard for PET/CT ﬁndings
The ﬁnal diagnosis of recurrence and stage was made by histo-
pathology whenever available, correlation with other imaging
modalities together with clinical and imaging follow up for
at least 6 months.
The PET/CT ﬁnding was classiﬁed as true positive (lesion
was deﬁned as malignant with subsequent conﬁrmed tumour
involvement), true negative (lesion deﬁned as benign with no
further evidence of disease), false positive (lesion was deﬁned
as malignant or equivocal ‘‘probably malignant’’ with no fur-
ther evidence of disease), or false negative (lesion was deﬁned
as benign or equivocal ‘‘probably benign’’ showing subsequent
evidence of malignancy).
The sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV), and accuracy of PET/CT
were calculated by patients.
2.2.3. Results
The PET/CT interpretations were correct in 31/34 patients
(91.2%). Incorrect interpretations of PET/CT images occurred
in 3 patients (8.8%) (1 false positive and 2 false negative). Rea-
son for false positive was pulmonary nodule (Fig. 1). Whereas
false negatives were due to an axillary lymph node metastasis
in one patient and supra renal metastases in the other one.
Absence of disease was encountered in 13/34 patients
(38.23%) by clinical and imaging follow-up. The PET/CT was
considered pathological in 21/34 patients (61.76%). Among
the 21 positive studies, 3 patients (8.8%) had isolated loco-regio-
nal recurrence, 15 patients (44.1%) had distant metastasis and 3
patients (8.8%) had both regional and distant recurrence.
Eighty-eight regions of increased FDG uptake were de-
tected. Malignancy was diagnosed in 47/88 regions in the fol-
lowing distribution: chest wall (n= 1), regional LN
(n= 10), internal mammary LN (n= 1), mediastinal LN
(n= 6), retroperitoneal LN (n= 2), lung nodules (n= 3), li-
ver (n= 8), suprarenal gland (n= 2), peritoneal (n= 1), skel-
eton (n= 12), skin metastases (n= 1). PET/CT characterized
sites as 36 benign, 45 as malignant, 7 lesion as equivocal. There
were 45 true positive, 1 false positive, 40 true negative, 2 false
negative (Table 1).
In patients with known metastatic disease PET/CT detected
additional unknown metastases in 3/5 patients in this study.
The other metastatic sites identiﬁed were lymph nodes and
bone metastases (n= 1), peritoneal and abdominal lymph
nodes metastases (n= 1), and liver metastases (n= 1) (Fig. 2).
The accuracy of 18F-FDG PET/CT examinations were as-
sessed by histopathological conﬁrmation of suspicious lesion(n= 4), concurrent or subsequent imaging ﬁndings (CT
(n= 6), MR (n= 12), bone scan (n= 5), US (n= 2), fol-
low-up PET/CT imaging (n= 13 with 2 patients had >1 fol-
low up PET/CT examinations), or change the line of treatment
(n= 8). The follow-up duration varied from 6 to 15 months,
with a mean of 9.4 months (See Figs. 3 and 4).
PET/CT showed an overall diagnostic accuracy of 91.2%
with a sensitivity of 90.5% and a speciﬁcity of 92.3%. The
PPV and NPV were 95% and 85.7%, respectively.
Table 1 PET/CT ﬁndings in the regions with suspected malignancies.
Region Total No Positive Accuracy Negative Accuracy Equivocal
(Probably benign)
Accuracy Equivocal(Probably malignant) Accuracy
Chest wall 4 1 TP 2 TN 1 TN
Axillary lymph nodes 8 5 TP 2 2TN 1 FN
Internal mammary
lymph nodes
1 1 TP
Pectoral LNS 2 2 TP
Supra/ infra clavicular
lymph nodes
2 2 TP
Cervical lymph nodes 3 3 TN
Hilar or mediastinal
lymph nodes
6 6 TP
Lungs 6 4 3 TP 2 TN 1 FP
Liver 18 7 TP 10 TN 1 TP
Retroperitoneal
lymph nodes
2 2 TP
Supra renal glands 3 1 TP 1 TN 1 FN
Peritoneum 1 1 TP
Bone metastases 12 12 TP
Skin 1 1 TP
Other sites 18 18 TN
Other sites of uptake include: Uterine ﬁbroid (n= 1), cyclic changes in ovary (n= 2), ovarian cyst (n= 1), thyroid nodules (n= 3), uptake in
the oropharynx (n= 1), uptake in the palatine tonsils (n= 3), uptake in the sternomastoid and respiratry muscles (n= 1), pulmonary
consolidation (n= 1), degenerative changes in the spine and hip joint (n= 1), degenerative changes in acromiocalvicular and shoulder joints
(n= 2), thrombosis of the Internal jagular and Brachiocephalic veins (n= 1), Thrombophlebitis (n= 1).
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Early diagnosis of loco-regional and metastatic disease is a
cornerstone in the oncological management of patients with
previously treated breast cancer. Loco-regional recurrence
may beneﬁt from curative treatment based on surgery and/
radiation therapy; where as distant metastases usually require
palliative systemic therapy. A diagnostic modality that is able
to scrutinize the true extent of the disease, including the num-
ber of sites and their localization would greatly improve these
patients’ management (2).
The added value of FDG-PET/CT compared to other diag-
nostic modalities is mainly expressed by the fact that a nonin-
vasive whole body evaluation is possible in a single
examination. It should be performed when there is strong sus-
picion of recurrent breast cancer disease (14).
In this study PET/CT has been shown to be useful in follow
up of patients with breast cancer and accurately stage meta-
static disease. In 43/52 PET/CT examinations, the CT part
was performed with contrast media. Thus, the CT component
was not used only for anatomic correlation, leading to in-
creased diagnostic value.
According to our results, the sensitivity of PET/ CT exam-
inations was 90.9% and speciﬁcity was 91.6%. The two false
negative ﬁndings were due to the small size of the suprarenal
lesion and axillary lymph node with low FDG uptake. They
were considered as lesions with low likelihood of malignancy.
The ﬁnal diagnosis was established by the progression seen in
the follow up PET/CT examination done after 6 m for the
adrenal lesion and 3 m for the axillary node. The false positive
study was due to FDG-avid pulmonary nodule. It was highly
suspicious as solitary metastases; however it disappeared on
follow up CT chest examination done 1 m later because of
deterioration of the patient symptoms.Tatsumi et al. had examined 69 patients, 61 of them were
examined because of suspected recurrence or for follow up.
Out of 61 patients PET/CT accurately staged 52, the sensitiv-
ity, speciﬁcity and accuracy for the total population evaluated
were 84%, 88%, 86%, respectively (15). A different group had
reported even a better performance for PET-CT with a sensi-
tivity of 100% (3).
In a large retrospective study, Manhor et al. investigated
111 patients with clinical suspicion of breast cancer recurrence
or metastatic disease using PET/CT. They had shown that
PET/CT is a very sensitive and speciﬁc tool in detecting and
restaging recurrent breast cancer. They reported sensitivity
and speciﬁcity of 98.7%, 85.3%, respectively (16).
Recently Aukema et al. had demonstrated that PET/CT
can detect distant metastases not visible on conventional imag-
ing in patients with conﬁrmed locoregional breast cancer
recurrence (17). In this study PET/CT was done for whole
body staging in already diagnosed cases of recurrence in 5 pa-
tients to assess the extent of the disease. In 3/5 patients PET/
CT revealed more metastatic sites in addition to those detected
on conventional imaging modalities.
The limitations of PET/CT in the detection of distant
metastases are poor sensitivity to detect brain metastases due
to high physiological FDG uptake, sclerotic bone metastases
and subcentimetric pulmonary nodules (17). In this series 2
cases showed solitary subcentimeteric non FDG avid pulmon-
ary nodule. The lesion size and absence of FDG uptake were
suggestive of its benign nature, thus we recommended close
follow up with non contrast CT scan. One nodule remained
stationary, whereas the other one disappeared after 6 m. This
was supported by the study done by Reinhardt el al. who sug-
gested close follow up for non FDG avid pulmonary nodules
(18). Evangelista et al. advised the follow up with CSCT in
Fig. 2 Forty-three year old patient with history of right breast carcinoma, which was treated with mastectomy, axillary lymph nodes
dissection, chemotherapy and radiotherapy. PET/CT was requested for whole-body staging due to newly depicted right axillary lymph
nodes. (a–c) PET/CT images showed more lymph node metastases, inﬁltration of the brachial plexus and the triceps brachii muscle, right
arm subcutaneous metastases together with wide spread osseous metastases.
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mend PET/CT considering its low spatial resolution (19).
The skeleton is the most common site of distant metasta-
ses in breast cancer (20). In this study 12 cases were diag-
nosed with bone metastases. Osteoblastic, osteolytic andmixed bone metastases were detected on CT images even
when PET ﬁndings were negative. In addition PET/CT was
able detect metastases at an early stage, when there is an in-
crease in metabolism with no morphologic abnormality de-
tected on CT.
Fig. 3 Thirty-two year old female patient with right breast
carcinoma underwent lumpectomy, followed by hormonal treat-
ment 3 months before PET/CT. (a and b) Axial PET and CT
images showed a focal area of increased glucose uptake at the left
iliac bone, with no corresponding morphologic changes on CT
image, suggested early metastases which were conﬁrmed by follow
up PET/CT done 1y later (c).
Fig. 4 Fifty-one year old female patient with history of the left
breast cancer. History of LITT of two hepatic focal lesions 2 and
4 months before PET/CT. (a-b) Fused PET/CT images showed
focal uptake at the margin of ablation site (a), complete
photopenia of segment VII focal lesion (complete ablation), with
small uptake at segment III suggestive of recurrence outside the
ablated area. Note uptake in the left rib metastases (b).
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tumour viability following previous treatments. Bone metasta-
ses are particularly difﬁcult to evaluate, since radiological
appearances often persist despite successful treatment. FDG-
PET/ CT might be of great advantage in this situation as it al-
lows deﬁnition of the metabolic activity of lesions seen on CT
(21). In this study 2 patients were evaluated after treatment of
bone metastases. The ﬁrst patient showed an osteolytic bone
lesion with no FDG uptake and gradual osteoblastic process
on sequential follow up PET/CT studies suggesting therapeutic
response. Whereas the second patient showed sclerotic bony le-
sions which remained FDG avid after treatment, suggesting tu-
mour variability with further progression of bone metastases in
the follow up PET/CT and MRI. This was an agreement with
the ﬁndings of Du et al. who followed bone metastases in pa-tients with recurrent breast cancer identiﬁed by FDG-PET/CT.
Their ﬁndings suggested that PET/CT uptake reﬂects the
immediate tumour activity of bone metastases independent
of morphological characteristics (22).
In this study 5 patients had pervious local ablative therapy
for liver metastases. Three out of ﬁve showed no uptake at the
ablated lesions, whereas the other two showed recurrence at
the site of ablation, with newly developed lesions in one of
them. This was supported by Barker et al. who had shown that
F-FDG PET and PET/CT are useful tools in follow up after
RFA of liver metastases to asses local tumour recurrence, in
addition PET/CT has the added beneﬁt precisely localizing
the most highly metabolic regions of tumour recurrence (23).
The limitations of this study include the small number of
patients with variable indications for the examination and its
retrospective nature. In addition, not all suspected lesions
had conﬁrmed histopathological veriﬁcation.
2.2.5. Conclusion
The current data support the integration of FDG-PET/CT in
the follow up and restaging algorithms in patients with breast
cancer showing high sensitivity and speciﬁcity.
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